Literature DB >> 26478210

Resolution Pharmacology: Opportunities for Therapeutic Innovation in Inflammation.

Mauro Perretti1, Xavier Leroy2, Elliot J Bland3, Trinidad Montero-Melendez4.   

Abstract

Current medicines for the clinical management of inflammatory diseases act by inhibiting specific enzymes or antagonising specific receptors or blocking their ligands. In the past decade, a new paradigm in our understanding of the inflammatory process has emerged with the appreciation of genetic, molecular, and cellular mechanisms that are engaged to actively resolve inflammation. The 'resolution of acute inflammation' is enabled by counter-regulatory checkpoints to terminate the inflammatory reaction, promoting healing and repair. It may be possible to harness this knowledge for innovative approaches to the treatment of inflammatory pathologies. Here we discuss current translational attempts to develop agonists at proresolving targets as a strategy to rectify chronic inflammatory status. We reason this new approach will lead to the identification of better drugs that will establish a new branch of pharmacology, 'resolution pharmacology'.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26478210     DOI: 10.1016/j.tips.2015.07.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  76 in total

Review 1.  Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms.

Authors:  Charles N Serhan
Journal:  FASEB J       Date:  2017-01-13       Impact factor: 5.191

Review 2.  Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology.

Authors:  Charles N Serhan
Journal:  Mol Aspects Med       Date:  2017-03-03

3.  Identification of Chemotype Agonists for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions.

Authors:  Nan Chiang; Elena Barnaeva; Xin Hu; Juan Marugan; Noel Southall; Marc Ferrer; Charles N Serhan
Journal:  Cell Chem Biol       Date:  2018-12-13       Impact factor: 8.116

Review 4.  Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors.

Authors:  Nan Chiang; Charles N Serhan
Journal:  Mol Aspects Med       Date:  2017-03-31

Review 5.  Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.

Authors:  Charles N Serhan; Bruce D Levy
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

6.  Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.

Authors:  Anna K Stalder; Dominik Lott; Daniel S Strasser; Hans G Cruz; Andreas Krause; Peter M A Groenen; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2016-11-15       Impact factor: 4.335

7.  Functional N-Formyl Peptide Receptor 2 (FPR2) Antagonists Based on the Ureidopropanamide Scaffold Have Potential To Protect Against Inflammation-Associated Oxidative Stress.

Authors:  Madia L Stama; Enza Lacivita; Liliya N Kirpotina; Mauro Niso; Roberto Perrone; Igor A Schepetkin; Mark T Quinn; Marcello Leopoldo
Journal:  ChemMedChem       Date:  2017-11-07       Impact factor: 3.466

8.  Proresolving lipid mediators enhance PMN-mediated bacterial clearance.

Authors:  Lucy V Norling; Mauro Perretti
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-16       Impact factor: 11.205

9.  Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.

Authors:  Letizia Crocetti; Claudia Vergelli; Gabriella Guerrini; Niccolò Cantini; Liliya N Kirpotina; Igor A Schepetkin; Mark T Quinn; Carmen Parisio; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Maria Paola Giovannoni
Journal:  Bioorg Chem       Date:  2020-04-28       Impact factor: 5.275

Review 10.  Paradigm shift - Metabolic transformation of docosahexaenoic and eicosapentaenoic acids to bioactives exemplify the promise of fatty acid drug discovery.

Authors:  Ganesh V Halade; Laurence M Black; Mahendra Kumar Verma
Journal:  Biotechnol Adv       Date:  2018-02-28       Impact factor: 14.227

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.